{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:43:18Z","timestamp":1792784598521,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ludemann Family Fund"},{"name":"MD Anderson Cancer Center Ovarian Cancer Moonshot"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA217685"],"award-info":[{"award-number":["CA217685"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013028","name":"Frank McGraw Memorial Chair in Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ygyno.2020.06.498","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T01:49:29Z","timestamp":1595382569000},"page":"653-658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance"],"prefix":"10.1016","volume":"158","author":[{"given":"Lauren P.","family":"Cobb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte C.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revathy","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpa M.","family":"Nick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole D.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwong K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvio G.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ygyno.2020.06.498_bb0005","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2020.06.498_bb0010","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer."},{"issue":"3","key":"10.1016\/j.ygyno.2020.06.498_bb0015","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/IGC.0b013e31823de6ae","article-title":"Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data","volume":"22","author":"Polterauer","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2020.06.498_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2016.05.022","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline","volume":"143","author":"Wright","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2020.06.498_bb0025","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9990","key":"10.1016\/j.ygyno.2020.06.498_bb0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.ygyno.2020.06.498_bb0035","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ygyno.2006.06.025","article-title":"Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis","volume":"103","author":"Bristow","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.06.498_bb0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2010.06.021","article-title":"The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists","volume":"119","author":"Dewdney","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.06.498_bb0045","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2016.01.008","article-title":"Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center","volume":"140","author":"Mueller","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.06.498_bb0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ygyno.2013.08.005","article-title":"Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience","volume":"131","author":"Fagotti","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.06.498_bb0055","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/AOG.0000000000002796","article-title":"Laparoscopic surgical algorithm to triage the timing of tumor reductive surgery in advanced ovarian cancer","volume":"132","author":"Fleming","year":"2018","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.06.498_bb0060","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.06.498_bb0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.06.498_bb0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.06.498_bb0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.498_bb0080","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.humpath.2018.10.020","article-title":"Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network","volume":"85","author":"Sehouli","year":"2019","journal-title":"Hum. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.06.498_bb0085","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2020.06.498_bb0090","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1179\/his.1997.20.2.145","article-title":"Antigen retrieval immunohistochemistry: practice and development","volume":"20","author":"Shi","year":"1997","journal-title":"J. Histotechnol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.06.498_bb0095","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1038\/s41598-018-21757-4","article-title":"InForm software: a semi-automated research tool to identify presumptive human hepatic progenitor cells, and other histological features of pathological significance","volume":"8","author":"Kramer","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ygyno.2020.06.498_bb0100","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12885-019-5514-7","article-title":"Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)","volume":"19","author":"Chung","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2020.06.498_bb0105","first-page":"560","article-title":"The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a Gynecologic Oncology Group study","volume":"132","author":"Fader","year":"2014","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.06.498_bb0110","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e4","article-title":"The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer","volume":"30","author":"Bogani","year":"2019","journal-title":"J Gynecol Oncol."},{"key":"10.1016\/j.ygyno.2020.06.498_bb0115","doi-asserted-by":"crossref","unstructured":"Gourley C. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas. Int J Gynecol Cancer. 24(9 suppl 3):S9-S13.","DOI":"10.1097\/IGC.0000000000000257"},{"issue":"4","key":"10.1016\/j.ygyno.2020.06.498_bb0120","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/pgp.0b013e31803025cd","article-title":"Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis","volume":"26","author":"Wong","year":"2007","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"12","key":"10.1016\/j.ygyno.2020.06.498_bb0125","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","article-title":"Ovarian carcinoma subtypes are different diseases: implications for biomarker studies","volume":"5","author":"K\u00f6bel","year":"2008","journal-title":"PLoS Med."},{"issue":"10","key":"10.1016\/j.ygyno.2020.06.498_bb0130","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.06.498_bb0135","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.06.498_bb0140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2017.07.127","article-title":"Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival?","volume":"147","author":"Fader","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2020.06.498_bb0145","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/IGC.0000000000000190","article-title":"Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer","volume":"24","author":"Grisham","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.06.498_bb0150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2017.01.027","article-title":"Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: a single institution experience","volume":"145","author":"Dalton","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2020.06.498_bb0155","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1158\/1078-0432.CCR-14-1292","article-title":"Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver","volume":"20","author":"Emmanuel","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.06.498_bb0160","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2353\/ajpath.2010.100212","article-title":"BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas","volume":"177","author":"Wong","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2020.06.498_bb0165","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.3967","article-title":"Low-grade serous carcinomas of the ovary contain very few point mutations","volume":"226","author":"Jones","year":"2012","journal-title":"J. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.06.498_bb0170","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.06.498_bb0175","first-page":"A1","article-title":"1 MILO\/ENGOT-OV11: phase 3 study of binimetinib versus physician\u2019s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","volume":"29","author":"Grisham","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl_5","key":"10.1016\/j.ygyno.2020.06.498_bb0180","first-page":"v851","article-title":"A randomized phase II\/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer","volume":"30","author":"Gershenson","year":"2019","journal-title":"Ann Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2020.06.498_bb0185","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vermurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820323246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820323246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:50:10Z","timestamp":1758772210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820323246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0090825820323246"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.06.498","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.06.498","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}